TOPFUND WHERE YOUR MONEY GROWS
Home / Stocks / Sun Pharmaceutical Ind L
SUNPHARMA

Sun Pharmaceutical Ind L Share Price

Live price, chart and which mutual funds hold this stock

TopFund Score: 75/100 · Good See breakdown ↓
…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 25 Sep 2026

₹1,852.2

Change

+2.3 (0.12%)

Open

₹1,858.7

Prev. Close

₹1,849.9

Day High

₹1,858.7

Day Low

₹1,841.6

Volume Analysis

Traded

683,246

Delivered

402,844

Delivery %

58.96%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (1)

  • •Strong operating margin (30.0%)

Weaknesses (0)

No signal for this stock

Opportunities (0)

No signal for this stock

Threats (1)

  • •FII holding has been falling

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹1,877.16 ₹1,867.93 ₹1,860.06 ₹1,850.83 ₹1,842.96 ₹1,833.73 ₹1,825.86
Fibonacci ₹1,867.93 ₹1,861.4 ₹1,857.36 ₹1,850.83 ₹1,844.3 ₹1,840.26 ₹1,833.73
Camarilla ₹1,856.9 ₹1,855.34 ₹1,853.77 ₹1,850.83 ₹1,850.63 ₹1,849.07 ₹1,847.5

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

+7.62%

1 Week

-0.89%

1 Month

-3.53%

3 Months

-0.55%

6 Months

+7.16%

1 Year

+16.73%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹612.04

Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

14.2%

Net margin 20.23% × asset turnover 0.54x × equity multiplier 1.3x

Company Overview

Sector

Healthcare

Market Cap

₹444,405 Cr

P/E (TTM)

35.2

ROE

16.0%

Book Value

₹348.0

Face Value

₹1.0

Source: Screener.in (Consolidated figures) — data as of 27 Sep 2026. Not investment advice.

TopFund Analysis

Sun Pharmaceutical Ind L holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 75/100. The strongest factor is Financial Strength (100/100), while Valuation (32/100) is the weakest area to weigh before deciding. Notably: Strong operating margin (30.0%). FII holding has been falling.

TopFund Score — Fundamentals Quality

75/100 — Good

Data confidence: 79/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.

As of 27 Sep 2026 · How we calculate this →

Financial Strength

100

Growth

65

Valuation

32

Cash Flow

70

Corporate Governance

90

Momentum

60

Institutional Ownership

57

Business Quality

89

Risk & Volatility

96

Liquidity

89

From Screener.in

  • +Company is almost debt free.
  • +Company has been maintaining a healthy dividend payout of 34.1%
  • −The company has delivered a poor sales growth of 11.8% over past five years.

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Receipt Of Approval Of The Shareholders For Reclassification Of Shareholder Category 26 Sep

Shareholders approved reclassification of certain promoter group persons to public on 26 September 2026.

Closure of Trading Window 25 Sep 25 Sep
Announcement under Regulation 30 (LODR)-Investor Presentation 22 Sep 22 Sep
Intimation Under Regulation 30 Of SEBI LODR 11 Sep

Sun Pharma subsidiaries settled a U.S. antitrust plaintiff claim for a confidential amount on 11 September 2026.

Incorporation Of A Subsidiary Company 09 Sep

Sun Pharma incorporated GIFT City treasury subsidiary on 8 Sep 2026; initial equity subscription about INR 9.50 crore.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
Sales + 11,941 12,192 12,381 11,983 12,653 13,291 13,675 12,959 13,851 14,478 15,521 14,612 15,300
Expenses + 8,609 9,013 8,904 8,948 9,045 9,352 9,666 9,243 9,550 9,951 10,572 10,658 10,882
Operating Profit 3,332 3,179 3,477 3,035 3,608 3,939 4,009 3,716 4,302 4,527 4,948 3,954 4,418
OPM % 28.0% 26.0% 28.0% 25.0% 29.0% 30.0% 29.0% 29.0% 31.0% 31.0% 32.0% 27.0% 29.0%
Other Income + -118 294 180 504 533 354 149 251 -354 470 89 458 520
Interest 81 49 35 74 62 69 52 49 75 100 78 86 100
Depreciation 651 633 622 650 655 626 631 664 701 730 732 775 739
Profit before tax 2,481 2,791 3,000 2,816 3,424 3,598 3,476 3,254 3,173 4,168 4,227 3,551 4,099
Tax % 19.0% 14.0% 14.0% 5.0% 16.0% 16.0% 16.0% 34.0% 27.0% 25.0% 20.0% 23.0% 29.0%
Net Profit + 2,006 2,385 2,561 2,659 2,861 3,037 2,913 2,154 2,293 3,125 3,381 2,710 2,901
EPS in Rs 8 10 11 11 12 13 12 9 10 13 14 11 12
Raw PDF — — — — — — — — — — — — —

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 27,392 28,487 31,578 26,489 29,066 32,838 33,498 38,654 43,886 48,497 52,578 58,462 59,911
Expenses + 19,498 20,313 21,476 20,858 22,689 25,855 25,028 28,397 32,235 35,479 37,464 41,961 42,063
Operating Profit 7,894 8,174 10,102 5,631 6,377 6,983 8,470 10,258 11,650 13,018 15,114 16,501 17,847
OPM % 29.0% 29.0% 32.0% 21.0% 22.0% 21.0% 25.0% 27.0% 27.0% 27.0% 29.0% 28.0% 30.0%
Other Income + 283 -42 610 -135 -258 382 -3,449 -3,505 459 865 1,444 1,895 1,537
Interest 579 523 400 518 555 303 141 127 172 238 231 339 364
Depreciation 1,195 1,038 1,265 1,500 1,753 2,053 2,080 2,144 2,529 2,557 2,575 2,938 2,976
Profit before tax 6,403 6,571 9,048 3,479 3,810 5,010 2,799 4,481 9,408 11,088 13,752 15,119 16,045
Tax % 14.0% 14.0% 13.0% 26.0% 16.0% 16.0% 18.0% 24.0% 9.0% 13.0% 20.0% 24.0% —
Net Profit + 5,476 5,658 7,846 2,542 3,208 4,172 2,272 3,389 8,513 9,610 10,965 11,509 12,117
EPS in Rs 22 19 29 9 11 16 12 14 35 40 46 48 50
Dividend Payout % 14.0% 5.0% 12.0% 23.0% 25.0% 25.0% 62.0% 73.0% 33.0% 34.0% 35.0% 33.0% —

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Reserves 25,431 32,742 36,400 38,074 41,169 45,025 46,223 47,771 55,755 63,427 71,978 83,330
Borrowings + 8,996 8,497 9,832 10,385 10,514 8,315 3,869 1,290 6,886 3,274 2,362 4,627
Other Liabilities + 14,089 13,948 14,624 15,598 12,666 14,615 17,291 20,474 17,831 18,387 17,328 20,210
Total Liabilities 48,723 55,428 61,095 64,297 64,590 68,194 67,622 69,776 80,712 85,328 91,908 108,407
Fixed Assets + 12,682 15,872 17,675 18,853 21,837 22,847 21,553 22,665 24,065 23,248 22,586 32,822
CWIP 2,039 2,175 2,801 2,465 1,411 1,220 1,567 1,287 4,973 5,354 6,644 3,052
Investments 2,716 1,830 1,192 7,143 7,903 10,143 9,612 12,849 14,824 15,026 18,354 24,723
Other Assets + 31,286 35,550 39,427 35,837 33,439 33,984 34,890 32,975 36,849 41,700 44,324 47,811
Total Assets 48,723 55,428 61,095 64,297 64,590 68,194 67,622 69,776 80,712 85,328 91,908 108,407
Equity Capital 207 241 240 240 240 240 240 240 240 240 240 240

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + 5,616 6,686 7,082 3,907 2,196 6,555 6,170 8,985 4,959 12,135 14,072 12,419
Cash from Investing Activity + -1,502 -3,949 -4,186 -3,104 -310 -2,225 407 -5,556 -7,220 -763 -5,183 -10,405
Cash from Financing Activity + -1,187 -1,889 -2,285 -1,539 -2,731 -5,715 -5,980 -5,193 2,376 -6,710 -7,906 -2,513
Net Cash Flow 2,927 848 611 -736 -844 -1,386 596 -1,765 115 4,662 983 -498
CFO/OP 93 106 90 83 48 113 85 78 56 105 96 89
Free Cash Flow 3,316 3,353 3,492 2,013 -966 5,105 5,097 7,550 2,895 9,964 12,005 8,906

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 54.48% → 54.48%
  Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
Public 9.05% 8.92% 8.97% 9.0% 8.89% 8.92% 8.86% 8.76% 8.72% 8.57% 8.48% 8.81%
Promoters 54.48% 54.48% 54.48% 54.48% 54.48% 54.48% 54.48% 54.48% 54.48% 54.48% 54.48% 54.48%
Government 0.1% 0.11% 0.11% 0.11% 0.11% 0.11% 0.11% 0.11% 0.11% 0.11% 0.11% 0.11%
FII 16.78% 17.08% 17.72% 17.23% 18.01% 18.04% 17.96% 17.26% 16.55% 16.12% 15.94% 14.54%
DII 19.56% 19.42% 18.71% 19.17% 18.48% 18.43% 18.58% 19.38% 20.12% 20.72% 21.0% 22.06%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Sun Pharmaceutical Ind L (this stock) 444,405 35.2 5.32 16.0%
Divi S Laboratories Ltd 255,487 85.8 15.25 16.5%
Torrent Pharmaceuticals L 189,746 85.0 20.11 27.4%
Apollo Hospitals Enter. L 128,055 60.9 13.51 21.2%
Zydus Lifesciences Ltd 120,089 24.7 4.48 21.2%
Cipla Ltd 111,060 31.0 3.23 11.6%
Laurus Labs Limited 108,438 99.2 20.44 18.3%

Which Mutual Funds Hold Sun Pharmaceutical Ind L?

Frequently Asked Questions about Sun Pharmaceutical Ind L

Community Sentiment

What are other investors saying about Sun Pharmaceutical Ind L?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.